--- title: "VXRT.US (VXRT.US) — Related News" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/VXRT.US/news.md" symbol: "VXRT.US" name: "VXRT.US" parent: "https://longbridge.com/en/quote/VXRT.US.md" datetime: "2026-05-20T09:32:12.909Z" locales: - [en](https://longbridge.com/en/quote/VXRT.US/news.md) - [zh-CN](https://longbridge.com/zh-CN/quote/VXRT.US/news.md) - [zh-HK](https://longbridge.com/zh-HK/quote/VXRT.US/news.md) --- # VXRT.US (VXRT.US) — Related News ### [Vaxart Urges Shareholder Support Amid Proxy Contest, Updates Pipeline](https://longbridge.com/en/news/286974394.md) *2026-05-19T22:48:10.000Z* > Vaxart (VXRT) has urged shareholders to support its board nominees amid a proxy contest, emphasizing the importance of e ### [Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027](https://longbridge.com/en/news/286969427.md) *2026-05-19T21:23:00.000Z* > Vaxart has filed a preliminary proxy and urged shareholders to support its board as it progresses with a Phase 2b COVID- ### [Vaxart submits initial proxy statement and sends letter to investors in recent development.](https://longbridge.com/en/news/286961930.md) *2026-05-19T20:02:52.000Z* > Vaxart has submitted an initial proxy statement and communicated with investors regarding recent developments. Additiona ### [09:06 ETJury Returns Full Defense Verdict for Armistice Capital and Its Executives in Vaxart Securities Class Action](https://longbridge.com/en/news/286422512.md) *2026-05-14T13:07:19.000Z* > A California federal jury has returned a complete defense verdict for Armistice Capital LLC and its executives, clearing ### [07:00 ETAltesa BioSciences Enrolls First Patient in Phase 2b CARDINAL Clinical Trial Evaluating Vapendavir as Transformational Treatment for Patients with COPD Impacted by Rhinovirus, the Leading Cause of Exacerbations](https://longbridge.com/en/news/285191627.md) *2026-05-05T11:00:40.000Z* > Altesa BioSciences has enrolled its first patient in the Phase 2b CARDINAL clinical trial, evaluating vapendavir as a tr ### [Vaxart (VXRT) Expected to Announce Quarterly Earnings on Monday](https://longbridge.com/en/news/285100795.md) *2026-05-04T17:00:15.000Z* > Vaxart (OTCMKTS:VXRT) is set to announce its Q1 2026 earnings on May 11, with expectations of $0.02 earnings per share a ### [Vaxart | 10-K: FY2025 Revenue Beats Estimate at USD 237.26 M](https://longbridge.com/en/news/283964597.md) *2026-04-24T08:54:09.000Z* ### [Vaxart Adds Veteran Biotech Leader to Board](https://longbridge.com/en/news/283900616.md) *2026-04-23T22:09:40.000Z* > Vaxart, Inc. has appointed James B. Breitmeyer, M.D., Ph.D., a veteran biotech executive, to its Board of Directors. Thi ### [Vax appoints James B. Breitmeyer to its Board](https://longbridge.com/en/news/283892156.md) *2026-04-23T20:53:01.000Z* > Vax has appointed James B. Breitmeyer, M.D., Ph.D. to its Board of Directors, effective immediately. He is the current C